Cancer treatment and research - 9780387731605 - advances in breast cancer management: 141 (19 risultati)
Lingua: Inglese
Editore: Springer, 2007
- Rilegato
Da: Basi6 International, Irving, TX, U.S.A.Basi6 International
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 25,58
Spedizione gratuitaSpedito in U.S.A.Quantità: 1 disponibili
Condizione: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.
Lingua: Inglese
Editore: Springer, 2007
- Rilegato
Da: Basi6 International, Irving, TX, U.S.A.Basi6 International
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 30,57
Spedizione gratuitaSpedito in U.S.A.Quantità: 1 disponibili
Condizione: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.
Lingua: Inglese
Editore: Springer, 2007
- Rilegato
Da: Romtrade Corp., STERLING HEIGHTS, MI, U.S.A.Romtrade Corp.
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 51,97
Spedizione gratuitaSpedito in U.S.A.Quantità: 1 disponibili
Condizione: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
Lingua: Inglese
Editore: Springer, 2007
- Rilegato
Da: Books Puddle, New York, NY, U.S.A.Books Puddle
Contatta il venditoreVenditore con 4 stelleCondizione: Nuovo
EUR 51,15
EUR 3,44 spedizioneSpedito in U.S.A.Quantità: 4 disponibili
Condizione: New. pp. x + 182 2nd Edition.
Lingua: Inglese
Editore: Springer, 2007
- Rilegato
Da: Majestic Books, Hounslow, Regno UnitoMajestic Books
Contatta il venditoreVenditore con 4 stelleCondizione: Nuovo
EUR 47,71
EUR 7,56 spedizioneSpedito da Regno Unito a U.S.A.Quantità: 4 disponibili
Condizione: New. pp. x + 182.
Lingua: Inglese
Editore: Springer, 2007
- Rilegato
Da: Biblios, frankfurt am main, HESSE, GermaniaBiblios
Contatta il venditoreVenditore con 4 stelleCondizione: Nuovo
EUR 49,00
EUR 9,95 spedizioneSpedito da Germania a U.S.A.Quantità: 4 disponibili
Condizione: New. pp. x + 182.
Lingua: Inglese
Editore: Springer, 2007
- Rilegato
Da: Romtrade Corp., STERLING HEIGHTS, MI, U.S.A.Romtrade Corp.
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 82,94
Spedizione gratuitaSpedito in U.S.A.Quantità: 5 disponibili
Condizione: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
Lingua: Inglese
Editore: Springer, 2007
- Rilegato
Da: Basi6 International, Irving, TX, U.S.A.Basi6 International
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 82,94
Spedizione gratuitaSpedito in U.S.A.Quantità: 8 disponibili
Condizione: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.
Lingua: Inglese
Editore: Springer, 2007
- Rilegato
Da: SMASS Sellers, IRVING, TX, U.S.A.SMASS Sellers
Contatta il venditoreVenditore con 4 stelleCondizione: Nuovo
EUR 86,30
Spedizione gratuitaSpedito in U.S.A.Quantità: 5 disponibili
Condizione: New. Brand New Original US Edition. Customer service! Satisfaction Guaranteed.
Lingua: Inglese
Editore: Springer, 2007
- Rilegato
Da: Romtrade Corp., STERLING HEIGHTS, MI, U.S.A.Romtrade Corp.
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 100,94
Spedizione gratuitaSpedito in U.S.A.Quantità: 1 disponibili
Condizione: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
Lingua: Inglese
Editore: SP SPRINGER, 2008
- Rilegato
- Edizione Internazionale
Da: UK BOOKS STORE, London, LONDO, Regno UnitoUK BOOKS STORE
Contatta il venditoreVenditore con 5 stelleEdizione InternazionaleCondizione: Nuovo
EUR 108,65
Spedizione gratuitaSpedito da Regno Unito a U.S.A.Quantità: Più di 20 disponibili
Condizione: New. Brand New! Fast Delivery This is an International Edition and ship within 24-48 hours. Deliver by FedEx and Dhl, & Aramex, UPS, & USPS and we do accept APO and PO BOX Addresses. Order can be delivered worldwide within 6-10 days and we do have flat rate for up to 2LB. Extra shipping charges will be requested if t…he Book weight is more than 5 LB. This Item May be shipped from India, United states & United Kingdom. Depending on your location and availability.
Lingua: Inglese
Editore: Springer, 2007
- Rilegato
Da: BennettBooksLtd, Los Angeles, CA, U.S.A.BennettBooksLtd
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 107,21
EUR 5,98 spedizioneSpedito in U.S.A.Quantità: 1 disponibili
Hardcover. Condizione: New. In shrink wrap. Looks like an interesting title.
Lingua: Inglese
Editore: Springer US, 2007
- Rilegato
Da: Buchpark, Trebbin, GermaniaBuchpark
Contatta il venditoreVenditore con 5 stelleCondizione: Usato - Ottimo
EUR 33,84
EUR 105,00 spedizioneSpedito da Germania a U.S.A.Quantità: 1 disponibili
Condizione: Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher | Over the last 5 years significant advances have been made in our understanding of the biology of breast cancer. As a result of linking observations made in the laboratory to new treatment strategies, the outcome of breast cancer patients with both… early and late stage disease has continued to improve. This volume will highlight many of the important advances that have improved our understanding of the biology and therapeutics of breast cancer. The initial discussion will focus on the evolving understanding of the genetics of breast cancer. (Olapade or Pasche) In addition to the well known genetic mutations BRCA1 and BRCA2, other mutations that have recently been identified will be discussed. In addition, strategies for surveillance of high-risk populations and prevention strategies under evaluation are highlighted. The underlying molecular pathways that control malignant cell growth are being better characterized thru laboratory investigation and as a result of this work numerous novel therapeutics that target these pathways in already in the clinic to define whether there is clinical benefit in breast cancer patients. Dr Pegram will discuss the rationale for development of some of the agents farthest along in clinical development. Though novel therapeutic agents or "targeted therapy" hold significant promise, standard treatment modalities including chemotherapy, endocrine therapy, surgery and radiation therapy will remain important for management of breast cancer patients. The decision to offer patients with early stage breast cancer systemic adjuvant therapy has been made based largely on clinical parameters including tumor size and nodal status. Clinicians have long recognized that this method of evaluating risk of recurrence for an individual patient is imprecise. Much research over the last several years has focused on developing molecular profiles of individual tumors that correlate with long-term outcome. Dr. Paik will discuss the development of this strategy and the results of the Oncotype DX Breast Cancer Assay, the first clinically available assay. In the last 5 years, the aromatase inhibitors have been investigated extensively as an alternative to tamoxifen or as a class of agents that adds to the effects of tamoxifen in postmenopausal woman with hormone receptor positive breast cancer. A review of the data from pivotal trials will be put in context by Dr O¿ Regan. Similarly, adjuvant chemotherapy has been refined in recent years to include taxanes and trastuzamab in select patients. Dr. Ravdin will highlight the findings from the most recent (2005) Oxford Overview of randomized clinical trials involving chemotherapy and tamoxifen. Dr Hudis will provide a critical analysis of the how recent data related to the incorporation of taxanes and trastuzamab in adjuvant therapy programs refines clinical decision-making. Local therapy in the form of radiation and surgery are critical components of the management of breast cancer patients. As more systemic therapy is administered in the preoperative setting, implications for breast conservation and management of the axilla are critical. Dr Newman will review the recent data that is relevant to this topic and Dr Hanson will place in context the role of sentinal lymph node biopsy and the controversies that remain regarding its use in certain situations. Finally Dr Vicini will review the emerging data related to new techniques of breast irradiation and how these potentially more patient "friendly" approaches compare to standard breast irradiation.
Lingua: Inglese
Editore: SPRINGER, 2008
- Rilegato
- Edizione Internazionale
Da: UK BOOKS STORE, London, LONDO, Regno UnitoUK BOOKS STORE
Contatta il venditoreVenditore con 5 stelleEdizione InternazionaleCondizione: Usato
EUR 236,62
Spedizione gratuitaSpedito da Regno Unito a U.S.A.Quantità: 3 disponibili
Hardcover. Condizione: New Books. Brand New! Fast Delivery This is an International Edition and ship within 24-48 hours. Deliver by FedEx and Dhl, & Aramex, UPS, & USPS and we do accept APO and PO BOX Addresses. Order can be delivered worldwide within 6-10 days and we do have flat rate for up to 2LB. Extra shipping charges will…be requested if the Book weight is more than 5 LB. This Item May be shipped from India, United states & United Kingdom. Depending on your location and availability.
Lingua: Inglese
Editore: Springer, 2007
- Rilegato
Da: Mispah books, Redhill, SURRE, Regno UnitoMispah books
Contatta il venditoreVenditore con 4 stelleCondizione: Usato - Come nuovo
EUR 274,51
EUR 29,10 spedizioneSpedito da Regno Unito a U.S.A.Quantità: 1 disponibili
Hardcover. Condizione: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.
Lingua: Inglese
Editore: Springer US, 2007
- Rilegato
- Print on Demand
Da: moluna, Greven, Germaniamoluna
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 132,75
EUR 48,99 spedizioneSpedito da Germania a U.S.A.Quantità: Più di 20 disponibili
Gebunden. Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Highlights many of the significant advances that have been made over the last 5 years to improve our understanding of the biology and therapeutics of breast cancerThis volume highlights many of the importan…t advances that have improved our understand.
Lingua: Inglese
Editore: Springer US Dez 2007, 2007
- Rilegato
- Print on Demand
Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermaniaBuchWeltWeit Ludwig Meier e.K.
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 160,49
EUR 23,00 spedizioneSpedito da Germania a U.S.A.Quantità: 2 disponibili
Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This volume highlights many of the important advances that have improved our understanding of the biology and therapeutics of breast cancer. The initial discussion focuses on the evolving understanding of the genetics of breast cancer. In… addition to the well known genetic mutations BRCA1 and BRCA2, other mutations that have recently been identified are discussed. 188 pp. Englisch.
Lingua: Inglese
Editore: Humana, 2007
- Rilegato
- Print on Demand
Da: AHA-BUCH GmbH, Einbeck, GermaniaAHA-BUCH GmbH
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 169,98
EUR 30,50 spedizioneSpedito da Germania a U.S.A.Quantità: 1 disponibili
Buch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Over the last 5 years significant advances have been made in our understanding of the biology of breast cancer. As a result of linking observations made in the laboratory to new treatment strategies, the outcome of breast cancer patients with…both early and late stage disease has continued to improve. This volume will highlight many of the important advances that have improved our understanding of the biology and therapeutics of breast cancer.The initial discussion will focus on the evolving understanding of the genetics of breast cancer. (Olapade or Pasche) In addition to the well known genetic mutations BRCA1 and BRCA2, other mutations that have recently been identified will be discussed. In addition, strategies for surveillance of high-risk populations and prevention strategies under evaluation are highlighted. The underlying molecular pathways that control malignant cell growth are being better characterized thru laboratory investigation and as a result of this work numerous novel therapeutics that target these pathways in already in the clinic to define whether there is clinical benefit in breast cancer patients. Dr Pegram will discuss the rationale for development of some of the agents farthest along in clinical development.Though novel therapeutic agents or 'targeted therapy' hold significant promise, standard treatment modalities including chemotherapy, endocrine therapy, surgery and radiation therapy will remain important for management of breast cancer patients. The decision to offer patients with early stage breast cancer systemic adjuvant therapy has been made based largely on clinical parameters including tumor size and nodal status. Clinicians have long recognized that this method of evaluating risk of recurrence for an individual patient is imprecise. Much research over the last several years has focused on developing molecular profiles of individual tumors that correlate with long-term outcome. Dr. Paik will discuss the development of this strategy and the results of the Oncotype DX Breast Cancer Assay, the first clinically available assay. In the last 5 years, the aromatase inhibitors have been investigated extensively as an alternative to tamoxifen or as a class of agents that adds to the effects of tamoxifen in postmenopausal woman with hormone receptor positive breast cancer. A review of the data from pivotal trials will be put in context by Dr O' Regan. Similarly, adjuvant chemotherapy has been refined in recent years to include taxanes and trastuzamab in select patients. Dr. Ravdin will highlight the findings from the most recent (2005) Oxford Overview of randomized clinical trials involving chemotherapy and tamoxifen. Dr Hudis will provide a critical analysis of the how recent data related to the incorporation of taxanes and trastuzamab in adjuvant therapy programs refines clinical decision-making.Local therapy in the form of radiation and surgery are critical components of the management of breast cancer patients. As more systemic therapy is administered in the preoperative setting, implications for breast conservation and management of the axilla are critical. Dr Newman will review the recent data that is relevant to this topic and Dr Hanson will place in context the role of sentinal lymph node biopsy and the controversies that remain regarding its use in certain situations. Finally Dr Vicini will review the emerging data related to new techniques of breast irradiation and how these potentially more patient 'friendly' approaches compare to standard breast irradiation.
Lingua: Inglese
Editore: Springer, Springer Dez 2007, 2007
- Rilegato
- Print on Demand
Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germaniabuchversandmimpf2000
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 160,49
EUR 60,00 spedizioneSpedito da Germania a U.S.A.Quantità: 1 disponibili
Buch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Over the last 5 years significant advances have been made in our understanding of the biology of breast cancer. As a result of linking observations made in the laboratory to new treatment strategies, the outcome of breast cancer patients with… both early and late stage disease has continued to improve. This volume will highlight many of the important advances that have improved our understanding of the biology and therapeutics of breast cancer.The initial discussion will focus on the evolving understanding of the genetics of breast cancer. (Olapade or Pasche) In addition to the well known genetic mutations BRCA1 and BRCA2, other mutations that have recently been identified will be discussed. In addition, strategies for surveillance of high-risk populations and prevention strategies under evaluation are highlighted. The underlying molecular pathways that control malignant cell growth are being better characterized thru laboratory investigation and as a result of this work numerous novel therapeutics that target these pathways in already in the clinic to define whether there is clinical benefit in breast cancer patients. Dr Pegram will discuss the rationale for development of some of the agents farthest along in clinical development.Though novel therapeutic agents or 'targeted therapy' hold significant promise, standard treatment modalities including chemotherapy, endocrine therapy, surgery and radiation therapy will remain important for management of breast cancer patients. The decision to offer patients with early stage breast cancer systemic adjuvant therapy has been made based largely on clinical parameters including tumor size and nodal status. Clinicians have long recognized that this method of evaluating risk of recurrence for an individual patient is imprecise. Much research over the last several years has focused on developing molecular profiles of individual tumors that correlate with long-term outcome. Dr. Paik will discuss the development of this strategy and the results of the Oncotype DX Breast Cancer Assay, the first clinically available assay.In the last 5 years, the aromatase inhibitors have been investigated extensively as an alternative to tamoxifen or as a class of agents that adds to the effects of tamoxifen in postmenopausal woman with hormone receptor positive breast cancer. A review of the data from pivotal trials will be put in context by Dr O¿ Regan. Similarly, adjuvant chemotherapy has been refined in recent years to include taxanes and trastuzamab in select patients. Dr. Ravdin will highlight the findings from the most recent (2005) Oxford Overview of randomized clinical trials involving chemotherapy and tamoxifen. Dr Hudis will provide a critical analysis of the how recent data related to the incorporation of taxanes and trastuzamab in adjuvant therapy programs refines clinical decision-making.Local therapy in the form of radiation and surgery are critical components of the management of breast cancer patients. As more systemic therapy is administered in the preoperative setting, implications for breast conservation and management of the axilla are critical. Dr Newman will review the recent data that is relevant to this topic and Dr Hanson will place in context the role of sentinal lymph node biopsy and the controversies that remain regarding its use in certain situations. Finally Dr Vicini will review the emerging data related to new techniques of breast irradiation and how these potentially more patient 'friendly' approaches compare to standard breast irradiation.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 188 pp. Englisch.
